Integrative Genomics Implicates EGFR as a Downstream Mediator in NKX2-1 Amplified Non-Small Cell Lung Cancer.

NKX2-1, encoding a homeobox transcription factor, is amplified in approximately 15% of non-small cell lung cancers (NSCLC), where it is thought to drive cancer cell proliferation and survival. However, its mechanism of action remains largely unknown. To identify relevant downstream transcriptional t...

Full description

Bibliographic Details
Main Authors: Nicole Clarke, Jewison Biscocho, Kevin A Kwei, Jean M Davidson, Sushmita Sridhar, Xue Gong, Jonathan R Pollack
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4640868?pdf=render
_version_ 1818251223949639680
author Nicole Clarke
Jewison Biscocho
Kevin A Kwei
Jean M Davidson
Sushmita Sridhar
Xue Gong
Jonathan R Pollack
author_facet Nicole Clarke
Jewison Biscocho
Kevin A Kwei
Jean M Davidson
Sushmita Sridhar
Xue Gong
Jonathan R Pollack
author_sort Nicole Clarke
collection DOAJ
description NKX2-1, encoding a homeobox transcription factor, is amplified in approximately 15% of non-small cell lung cancers (NSCLC), where it is thought to drive cancer cell proliferation and survival. However, its mechanism of action remains largely unknown. To identify relevant downstream transcriptional targets, here we carried out a combined NKX2-1 transcriptome (NKX2-1 knockdown followed by RNAseq) and cistrome (NKX2-1 binding sites by ChIPseq) analysis in four NKX2-1-amplified human NSCLC cell lines. While NKX2-1 regulated genes differed among the four cell lines assayed, cell proliferation emerged as a common theme. Moreover, in 3 of the 4 cell lines, epidermal growth factor receptor (EGFR) was among the top NKX2-1 upregulated targets, which we confirmed at the protein level by western blot. Interestingly, EGFR knockdown led to upregulation of NKX2-1, suggesting a negative feedback loop. Consistent with this finding, combined knockdown of NKX2-1 and EGFR in NCI-H1819 lung cancer cells reduced cell proliferation (as well as MAP-kinase and PI3-kinase signaling) more than knockdown of either alone. Likewise, NKX2-1 knockdown enhanced the growth-inhibitory effect of the EGFR-inhibitor erlotinib. Taken together, our findings implicate EGFR as a downstream effector of NKX2-1 in NKX2-1 amplified NSCLC, with possible clinical implications, and provide a rich dataset for investigating additional mediators of NKX2-1 driven oncogenesis.
first_indexed 2024-12-12T16:04:53Z
format Article
id doaj.art-57d73fe4e4db45acaf99895f5bedc23a
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-12T16:04:53Z
publishDate 2015-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-57d73fe4e4db45acaf99895f5bedc23a2022-12-22T00:19:19ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-011011e014206110.1371/journal.pone.0142061Integrative Genomics Implicates EGFR as a Downstream Mediator in NKX2-1 Amplified Non-Small Cell Lung Cancer.Nicole ClarkeJewison BiscochoKevin A KweiJean M DavidsonSushmita SridharXue GongJonathan R PollackNKX2-1, encoding a homeobox transcription factor, is amplified in approximately 15% of non-small cell lung cancers (NSCLC), where it is thought to drive cancer cell proliferation and survival. However, its mechanism of action remains largely unknown. To identify relevant downstream transcriptional targets, here we carried out a combined NKX2-1 transcriptome (NKX2-1 knockdown followed by RNAseq) and cistrome (NKX2-1 binding sites by ChIPseq) analysis in four NKX2-1-amplified human NSCLC cell lines. While NKX2-1 regulated genes differed among the four cell lines assayed, cell proliferation emerged as a common theme. Moreover, in 3 of the 4 cell lines, epidermal growth factor receptor (EGFR) was among the top NKX2-1 upregulated targets, which we confirmed at the protein level by western blot. Interestingly, EGFR knockdown led to upregulation of NKX2-1, suggesting a negative feedback loop. Consistent with this finding, combined knockdown of NKX2-1 and EGFR in NCI-H1819 lung cancer cells reduced cell proliferation (as well as MAP-kinase and PI3-kinase signaling) more than knockdown of either alone. Likewise, NKX2-1 knockdown enhanced the growth-inhibitory effect of the EGFR-inhibitor erlotinib. Taken together, our findings implicate EGFR as a downstream effector of NKX2-1 in NKX2-1 amplified NSCLC, with possible clinical implications, and provide a rich dataset for investigating additional mediators of NKX2-1 driven oncogenesis.http://europepmc.org/articles/PMC4640868?pdf=render
spellingShingle Nicole Clarke
Jewison Biscocho
Kevin A Kwei
Jean M Davidson
Sushmita Sridhar
Xue Gong
Jonathan R Pollack
Integrative Genomics Implicates EGFR as a Downstream Mediator in NKX2-1 Amplified Non-Small Cell Lung Cancer.
PLoS ONE
title Integrative Genomics Implicates EGFR as a Downstream Mediator in NKX2-1 Amplified Non-Small Cell Lung Cancer.
title_full Integrative Genomics Implicates EGFR as a Downstream Mediator in NKX2-1 Amplified Non-Small Cell Lung Cancer.
title_fullStr Integrative Genomics Implicates EGFR as a Downstream Mediator in NKX2-1 Amplified Non-Small Cell Lung Cancer.
title_full_unstemmed Integrative Genomics Implicates EGFR as a Downstream Mediator in NKX2-1 Amplified Non-Small Cell Lung Cancer.
title_short Integrative Genomics Implicates EGFR as a Downstream Mediator in NKX2-1 Amplified Non-Small Cell Lung Cancer.
title_sort integrative genomics implicates egfr as a downstream mediator in nkx2 1 amplified non small cell lung cancer
url http://europepmc.org/articles/PMC4640868?pdf=render
work_keys_str_mv AT nicoleclarke integrativegenomicsimplicatesegfrasadownstreammediatorinnkx21amplifiednonsmallcelllungcancer
AT jewisonbiscocho integrativegenomicsimplicatesegfrasadownstreammediatorinnkx21amplifiednonsmallcelllungcancer
AT kevinakwei integrativegenomicsimplicatesegfrasadownstreammediatorinnkx21amplifiednonsmallcelllungcancer
AT jeanmdavidson integrativegenomicsimplicatesegfrasadownstreammediatorinnkx21amplifiednonsmallcelllungcancer
AT sushmitasridhar integrativegenomicsimplicatesegfrasadownstreammediatorinnkx21amplifiednonsmallcelllungcancer
AT xuegong integrativegenomicsimplicatesegfrasadownstreammediatorinnkx21amplifiednonsmallcelllungcancer
AT jonathanrpollack integrativegenomicsimplicatesegfrasadownstreammediatorinnkx21amplifiednonsmallcelllungcancer